GlobeNewswire Inc.··NaMesoblast's Ryoncil Hits $30.3M in Q1 as First-Year Sales Near $100M Milestone
Mesoblast reports $30.3M quarterly sales for Ryoncil, its FDA-approved cell therapy for pediatric graft-versus-host disease, approaching $100M in first-year revenue.
MESOFDA approvalRyoncil®